Next Century Growth Investors’s Pacira BioSciences PCRX Stock Holding History

Next Century Growth Investors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,311	Closed	-$491K	–	152
2017 Q2	$491K	Buy	+10,311	New	+$478K	0.05%	147
2016 Q4	–	Sell	-778,442	Closed	-$26.6M	–	171
2016 Q3	$26.6M	Buy	778,442 +75,388	+11%	+$2.95M	1.22%	22
2016 Q2	$23.7M	Sell	703,054 -29,833	-4%	-$1.47M	1.11%	27
2016 Q1	$38.8M	Buy	732,887 +271,465	+59%	+$15.9M	1.83%	11
2015 Q4	$35.4M	Buy	+461,422	New	+$26.1M	1.53%	18
2015 Q2	–	Sell	-256,244	Closed	-$22.8M	–	204
2015 Q1	$22.8M	Sell	256,244 -303,956	-54%	-$30.8M	0.8%	38
2014 Q4	$49.7M	Sell	560,200 -208,196	-27%	-$19.7M	1.79%	12
2014 Q3	$74.5M	Sell	768,396 -199,242	-21%	-$19.4M	2.63%	2
2014 Q2	$88.9M	Sell	967,638 -232,591	-19%	-$17.7M	2.85%	1
2014 Q1	$84M	Buy	1,200,229 +357,527	+42%	+$24.3M	2.5%	1
2013 Q4	$48.4M	Buy	842,702 +519,675	+161%	+$27.3M	1.34%	18
2013 Q3	$15.5M	Buy	+323,027	New	+$11.8M	0.45%	69

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Next Century Growth Investors's PCRX Position: Q3 2017 in Review

Next Century Growth Investors sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 10,311 shares — an estimated $491K sold.

Next Century Growth Investors first reported a position in PCRX in Q3 2013 and held it in 12 quarters. The position peaked at $88.9M in Q2 2014. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

Next Century Growth Investors reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
Next Century Growth Investors sold 10,311 Pacira BioSciences shares in Q3 2017, an estimated $491K.
Next Century Growth Investors first reported a position in Pacira BioSciences in Q3 2013 and held it in 12 quarters.
Next Century Growth Investors's Pacira BioSciences position peaked at $88.9M in Q2 2014.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on Next Century Growth Investors's 13F filing for Q3 2017, filed 14 Nov 2017.